News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Talon Therapeutics, Inc. (TLON.OB) Announces Enrollment and Dosing of the First Patient in the Phase 3 Confirmatory Study of Marqibo(R) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (HALLMARQ Study)



6/1/2012 9:48:52 AM

SAN MATEO, Calif., June 1, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON - News) announced enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo(R) (vincristine sulfate liposome injection) in adults (60 years of age and older) with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL), known as the HALLMARQ Study.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES